SEF

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of SEF

Quick Facts

Property Description
Active ingredient Cephalexin (INN)
Forms Capsules, Tablets, Oral suspension
Pharmacological Class beta-Lactam antibiotic, First-generation cephalosporin
Common Use Treating bacterial infections (Antimicrobial therapy)
Origin Semisynthetic

What is SEF and What Drug Class Does it Belong To?

SEF is the trade name for a semisynthetic, prescription-only antibiotic whose sole active ingredient is Cephalexin. It belongs to the cephalosporin family, which is a subgroup of the wider beta-Lactam class of antimicrobial drugs. Cephalexin is precisely categorized as a first-generation cephalosporin, reflecting its chemical structure and established spectrum of activity. This classification reflects that the medicine is clinically recognized for its efficacy against many common Gram-positive bacteria, supported by decades of pharmacological studies.

First-generation cephalosporins remain a standard, reliable treatment option in antimicrobial therapy, owing to their established efficacy profile. This indicates that SEF offers a well-understood and effective means of fighting infection when susceptible bacteria are present.

How is SEF Classified and What is its General Purpose?

The mechanism of SEF defines it as a bactericidal agent, meaning its general purpose is to actively kill susceptible bacteria rather than simply stopping them from multiplying. This function is achieved by directly interfering with the synthesis of the bacterial cell wall. The drug's structure allows it to disrupt the final cross-linking step of peptidoglycan synthesis, which is critical for the cell wall's structural integrity, leading to pathogen elimination.

Composition, Origin, and Available Forms of SEF

SEF is a single-component product formulated for oral administration, distinguishing it from related agents that require injection. Its active ingredient, Cephalexin, is available in three common forms: capsules and tablets, as well as a powder for oral suspension. This suspension is often available in specific flavors to improve palatability for patient groups, such as children, enabling effective treatment in an outpatient setting.

Regulatory References

  1. Cephalexin: MedlinePlus Drug Information

What side effects are possible with SEF?

Possible Side Effects and Safety Information for SEF

The safety profile of SEF, as outlined in official regulatory documents (e.g., FDA and EMA), identifies both frequently reported and rare, serious adverse reactions. The most common adverse reactions tend to be gastrointestinal and neurological in nature.

Adverse Reaction Overview

Classification (Regulatory Basis) Examples of Reactions
Very Common (Frequency ge 1/10) Headache, Nausea
Common (Frequency ge 1/100 to < 1/10) Dizziness, Diarrhea, Vomiting, Fatigue, Rash, Upper Respiratory Tract Infection

The highest incidence of common reactions, particularly nausea and headache, is typically observed during the initiation of therapy and may diminish with continued use.

Serious Safety Considerations

Serious Adverse Reactions

Clinically significant, serious adverse reactions documented in regulatory sources include Hepatotoxicity (liver damage), Anaphylactic Reaction (a severe, life-threatening allergic reaction), and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS).

Restrictions and Safety Monitoring

Use of SEF is formally contraindicated in individuals with known hypersensitivity to the drug substance or excipients, as well as in those with severe hepatic impairment. Due to the established risk of hepatotoxicity, regulatory labeling mandates baseline and periodic monitoring of liver function tests (LFTs), particularly upon initiating treatment and following any dose adjustments. Immediate and permanent discontinuation of SEF is required if signs of clinically significant liver injury or severe allergic reactions occur. Caution and potential dose modification are also advised for specific populations, including those with pre-existing renal impairment, as exposure may be affected.

The official documentation structures the understanding of SEF's risks by framing common, manageable side effects against the need for strict vigilance and biological monitoring to mitigate rare but potentially life-threatening systemic and dermatological risks.

Overdose and Emergency Response

The official regulatory documents state that an overdose of SEF (Cephalexin) may primarily present with gastrointestinal distress, including nausea, vomiting, diarrhea, and abdominal pain. A specific clinical manifestation reported in regulatory labeling is haematuria (blood in the urine), which may appear pink, red, or dark brown.

The most serious, officially documented outcomes involve the Central Nervous System (CNS), with the potential for neurotoxicity that can include seizures, myoclonus, or encephalopathy. This risk is specifically noted to be higher for individuals with impaired renal function if dosage is not appropriately managed. Reports also indicate that children have experienced haematuria following accidental ingestion of high doses, even without impaired renal function.

Immediate medical attention is required for any suspected overdose. Emergency services must be contacted at once if the affected individual experiences life-threatening signs such as a seizure, collapse, trouble breathing, or inability to be awakened. There is no specific antidote listed in official labeling. Treatment is confined to general supportive care and close clinical and laboratory monitoring of haematological, hepatic, renal function, and coagulation status until stability is achieved. Gastrointestinal decontamination is generally unnecessary unless massive ingestion is confirmed.

Therapeutic Uses of SEF

SEF is generally used to provide supportive relief for acute, mild-to-moderate bacterial infections in various systems of the body, and it may assist with symptomatic relief. This medication is relevant across several key therapeutic domains.


Therapeutic Contexts and Symptom Management

This medication is commonly used across conditions characterized by periods of heightened symptoms such as skin and soft tissue infections (cellulitis, impetigo), specific respiratory tract infections (streptococcal pharyngitis, otitis media), and uncomplicated genitourinary infections (cystitis). It is also applied in specific, managed cases of bone infections.

It is applied in clinical settings that involve acute or unstable symptom patterns, addressing symptoms related to physical discomfort like localized swelling, redness, tenderness, and pain. It also helps manage symptoms such as fever, which are manifestations of systemic stress. This supportive relief helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods.

“This medication is generally used to help patients cope more steadily with difficult episodes marked by pronounced symptoms.”


Quick Fact

Quick Fact Description
Relief for Localized Discomfort Supports the easing of acute pain, tenderness, and inflammation in symptomatic tissue areas.
Therapeutic Context Applied across domains where additional symptomatic support is needed for common bacterial infections.
Patient Benefit Contributes to maintaining a sense of stability when symptoms are more noticeable, assisting with functional stability.

Regulatory References

  1. NIH MedlinePlus overview on Cephalexin

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Information

This section outlines who can and cannot use SEF, based exclusively on formal eligibility requirements and contraindications detailed in authoritative government regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).


Classification Rule and Required Condition
Absolute Contraindication The medicine must not be used in individuals with a known hypersensitivity to the active substance or to any non-active ingredient (excipients).
Conditional Use/Restricted Use in patients with moderate to severe renal or hepatic impairment requires special consideration and monitoring due to potential accumulation or altered clearance. Use is often not recommended in severe cases.
Non-Established Use Pediatric patients below a specified minimum age (e.g., children under 2 years) or specific weight categories are generally not eligible as safety and effectiveness have not been established by regulatory authorities.

Pregnancy and Lactation Eligibility Status:

  • Pregnancy: Use of SEF is generally not recommended or is contraindicated. Female patients of reproductive potential may be required to have a negative pregnancy test prior to starting therapy and use effective contraception during treatment.
  • Lactation: Use is not recommended; the official labeling requires a decision to be made to either discontinue nursing or discontinue the drug, based on risk factors.

Regulatory documents define a clear safety boundary: populations with absolute contraindications are legally excluded from use, while those in the restricted category are eligible only if mandatory conditions, such as rigorous monitoring and assessment of organ function, are met. These rules establish the formal constraints for use.

What should I know about interactions with other medicines?

The regulatory profile for Cephalexin (SEF) documents specific interaction patterns with other medicinal products and substances, classified primarily by their effect on drug clearance and systemic risk. No formal drug-drug combination is designated as a strict contraindication in official labeling.

Interactions Affecting Drug Exposure

Substance Interaction Mechanism and Outcome
Probenecid Inhibits the renal excretion of Cephalexin, leading to increased and prolonged plasma concentrations. Co-administration is not recommended in official regulatory sources.
Metformin Cephalexin co-administration increases the plasma concentrations and decreases the renal clearance of Metformin, an effect officially attributed to transporter-mediated interference.

Interactions Affecting Systemic Risk

Substance Category Interaction Mechanism and Outcome
Oral Anticoagulants Associated with a potential reduction in prothrombin activity, resulting in an officially documented increased risk of bleeding.
Nephrotoxic Agents Concurrent administration with other nephrotoxic agents (e.g., Loop Diuretics) carries a documented additive risk of organ toxicity.

Timing and Absorption Rules

Zinc-containing products officially reduce the absorption of Cephalexin. To mitigate this effect, a mandatory separation of at least three hours between the administration of Cephalexin and such supplements is required. The drug's clearance is significantly reduced in patients with impaired renal function, which heightens the relevance of these interactions and accumulation risk.

Mechanism of Action

Irreversible Inhibition of Bacterial Cell Wall Construction

SEF's core mechanism is the irreversible inactivation of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for the final cross-linking of the cell wall's peptidoglycan structure. The drug's bactericidal action results from the physical failure of the wall to maintain structural integrity, leading to the rapid osmotic lysis and death of susceptible pathogens.


️ Mechanistic Constraint by beta-Lactamase Enzymes

The physiological function of this mechanism is directly constrained by bacterial resistance factors, primarily the production of beta-Lactamase enzymes. These enzymes hydrolytically destroy the active part of the Cephalexin molecule before it can reach the PBP target, preventing the intended inhibitory action and leaving the pathogen's PBP targets unbound in resistant strains.

Dosage and Administration Information

How SEF is Used: Standard Administration Guidelines

SEF (Cephalexin) is designated exclusively for oral administration, utilizing available forms such as capsules, tablets, and a powder for oral suspension. The medication is classified as acid-stable, meaning it may be administered without regard to meals, as food does not significantly affect its total absorption.


Standard Dosing and Frequency

The standard adult daily dose ranges from 1 gram to 4 grams total, which must be administered in two to four equally divided doses per day, typically every 6 hours or every 12 hours. The maximum established dose for more severe infections is 4 grams daily. Treatment duration is generally 7 to 14 days, but a minimum course of 10 days is required when used for beta-hemolytic streptococcal infections.


Usage in Specific Contexts

Instruction Detail
Preparation Powder for oral suspension must be reconstituted with water before dispensing and requires shaking well before each measured dose.
Pediatric Dosing Dosing for children over one year of age is weight-based, generally 25 to 50 mg/kg daily, divided into multiple doses.
Renal Impairment Dose adjustment is required for adult and adolescent patients (ge 15 years) with severe renal impairment.
Tablet Use The score line on certain tablets is intended only to aid swallowing and is not intended to divide the tablet into equal doses.

These instructions define the established dosage range, the frequency pattern, and the duration constraints, structuring the standardized approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism and Action Profile

Research evaluated the drug's activity by inhibiting a key inflammatory pathway. This pathway was the subject of investigation for its relationship with pain and joint function. Research examined the drug's activity across various inflammatory markers in preclinical models. This activity was the subject of investigation in models of conditions such as rheumatoid arthritis.

  • Studies included research on the drug's half-life and concentration profiles in various patient groups.
  • Short-term trials included measurements of swelling and stiffness.

Clinical Trial Findings

Study 1: Pain and Mobility

Studies have explored whether the drug is associated with changes in mobility scores and pain reports in patients with chronic joint pain. The trials typically focused on patients experiencing mild-to-moderate discomfort.

  • In a Phase 3 study involving 500 participants, the drug combination's results were compared to placebo in assessments of pain relief.
  • Trial length varied, with follow-up periods ranging from 4 to 12 weeks.

Study 2: Long-Term Effects and Safety

Research into long-term use has primarily involved observational studies and extensions of initial Phase 2 trials.

  • The primary endpoints of these long-term studies included monitoring for major adverse cardiovascular events and other serious adverse reactions.
  • Studies have evaluated whether combining the drug with standard anti-inflammatory medications is associated with specific effects on clinical outcomes. The study protocols typically specified administration once daily.
  • It is not yet clear whether the long-term use of this compound leads to better overall outcomes compared to other established therapies.

Pharmacokinetic Observations

Research examined whether the drug was associated with a change in the frequency of flare-ups in a small cohort of patients (n=85) over a 6-month period.

  • Some studies reported observations of symptom changes within the first week of administration.
  • Studies evaluated safety measures in patients with mild pre-existing liver impairment.

Frequently Asked Questions (FAQ)

Common questions about SEF (FAQ)


Q: How quickly does SEF start to affect the body?

A: Studies on the drug's absorption indicate that the highest concentration in the bloodstream is typically reached about one hour after taking the medication orally. This is part of the pharmacokinetic (PK) data found in official prescribing information, which determines how the drug moves through the body.


Q: Can SEF cause weight gain?

A: According to the official product information, weight gain is not listed as one of the known or commonly reported adverse reactions. Regulatory documentation focuses only on side effects that have been clearly identified during clinical trials or post-market surveillance.


Q: Can people with high blood pressure take SEF?

A: Official regulatory labeling does not list high blood pressure as a specific contraindication (a reason the drug must not be used). The labeling suggests careful evaluation of overall health status for patients with underlying cardiovascular conditions, including hypertension, prior to beginning treatment.


Q: What happens if I miss a dose of SEF?

A: If a dose is missed, patient information typically advises taking it as soon as it is remembered. However, official patient information advises to skip the missed dose and resume the regular schedule if it is almost time for the next dose. It is generally advised not to take a double dose to make up for a missed one.


Q: Do I need a special diet while using SEF?

A: The official administration guidelines state that the medication is acid-stable and can be taken without regard to meals, as food does not significantly affect its total absorption into the body. Therefore, no general special diet is required.


Q: Is SEF safe to use with common pain relievers like ibuprofen?

A: The official regulatory document does not list a direct interaction between Cephalexin and common over-the-counter pain relievers such as Ibuprofen. As with any medication, reviewing all prescription and non-prescription drugs with a health professional is generally recommended.


Q: Does SEF affect sleep patterns?

A: Official documentation lists trouble sleeping (insomnia) as a reported adverse reaction. While the exact frequency of this side effect is not clearly established, it falls under the neurological effects that may occur during treatment.


Q: Can SEF be used by people over 65?

A: The adult dosing guidelines cover use in older patient populations. Since the drug is primarily cleared from the body by the kidneys, dosage adjustments may be required for older patients, who are more likely to have some decrease in kidney function.


Q: Is SEF safe for patients who have heart issues?

A: Official labeling does not list specific heart issues as an absolute contraindication for use. The labeling suggests careful evaluation of the condition by a health professional before starting therapy.


Q: Does SEF affect fertility or family planning?

A: Based on nonclinical studies required by regulatory bodies, Cephalexin did not affect fertility or reproductive performance in male and female rats at doses relevant to human use. This information is contained within the nonclinical toxicology section of the drug's official label.


Q: Does SEF interact with alcohol?

A: The official regulatory labeling does not state a specific or direct interaction between Cephalexin and alcohol. Unlike some other antibiotics, there is no formal warning of a disulfiram-like reaction (severe intolerance) listed in the documentation.


Q: Can SEF be taken with cold and flu medicine?

A: The official labeling does not include a general warning against all cold and flu medicines. Reviewing all components of prescription and non-prescription drugs with a health professional before co-administration is generally advised.


Q: What should I do if I suspect an unusual side effect from SEF?

A: Suspected adverse reactions are typically reported to the prescribing doctor. Furthermore, regulatory bodies encourage direct reporting; in the U.S., consumers can report reactions directly to the Food and Drug Administration (FDA) through the MedWatch program.


Q: Does the effectiveness of SEF decrease over time?

A: The regulatory assessment confirms the drug has not been withdrawn from the market for reasons of decreased overall effectiveness. The main risk to effectiveness is the development of drug-resistant bacteria if the drug is used inappropriately or for conditions it is not intended to treat.


Q: Is SEF available in different strengths?

A: Yes, the medication is manufactured and available in multiple oral strengths, as specified in the official regulatory documents. These include various strengths for capsules and tablets (e.g., 250 mg, 500 mg) and as a powder for oral suspension.


Q: Does SEF interact with birth control pills?

A: Official documentation notes a potential interaction with combined oral contraceptives (COCs) where the antibiotic may reduce the effectiveness of the birth control medication. Patients using COCs may need to use additional non-hormonal contraception during treatment.


Q: Why is SEF taken for an extended time in some cases?

A: Treatment periods are mandated by regulatory bodies to ensure the complete eradication of the infection. For example, a minimum course of 10 days is required when treating specific pathogens, such as beta-hemolytic streptococcal infections, to prevent subsequent complications.


Q: Is it okay to stop taking SEF if I feel better?

A: No. The full prescribed course of medication should be completed, even if symptoms improve quickly or disappear after a few days. Stopping the treatment early may lead to a recurrence of the infection or the development of antibiotic resistance.


Q: Are there any common foods that interact with SEF?

A: The medication is approved to be administered without regard to meals since food does not significantly affect its overall absorption. This means no specific foods are listed as having major interactions that affect how the drug works.


Q: Is SEF considered a 'strong' medicine?

A: The drug is officially classified as a bactericidal agent. This means its documented mechanism of action is to actively kill susceptible bacteria by destroying the cell wall, which confirms its direct and lethal effect on the target pathogens.


Q: How long does SEF stay in your system after stopping it?

A: The drug is known to be rapidly absorbed and substantially eliminated from the body. Measurable levels are generally present in the serum for about six hours following administration, which relates directly to its typical dosing frequency.


Q: Can SEF be taken with multivitamins or supplements?

A: Official labeling states that Zinc-containing products reduce the absorption of the medication. A mandatory separation of at least three hours between taking the drug and any zinc supplement is required.


Q: What is the difference in how SEF works compared to a traditional anti-inflammatory?

A: The mechanism of this drug is to actively kill susceptible bacteria by disrupting the synthesis of the bacterial cell wall (bactericidal action). This is distinct from anti-inflammatory agents, which work by inhibiting key inflammatory pathways within the body.


Q: Can SEF be used by teenagers?

A: Yes. Use in the adolescent age group is covered by the adult dosing guidelines, which typically apply to patients 15 years of age and older. Pediatric dosing is specified for children over one year of age.


Q: What does 'contraindicated' mean in relation to SEF?

A: A contraindication is a medical condition or factor that renders the use of the medication improper or harmful. In relation to this drug, contraindications are conditions where the medicine must not be used because it could cause significant harm to the patient.


Q: Is SEF safe for people with diabetes?

A: Official labeling does not list diabetes as a contraindication. However, the drug increases the plasma concentration and decreases the renal clearance of the common diabetes drug Metformin. This interaction should be discussed with a health professional.


Q: Can SEF be split or crushed?

A: The score line sometimes present on tablets is intended only to aid swallowing and is not intended to divide the tablet for the purpose of creating equal doses. Consultation with a health professional is typically required if the medication needs to be altered.


Q: What are the signs of a severe allergic reaction to SEF?

A: Signs of a serious allergic reaction may include rash, hives, swelling of the face, tongue, or throat, severe dizziness, and trouble breathing. Official labeling requires immediate and permanent discontinuation of the drug if these signs of Anaphylaxis or SCARs occur.


Q: Are there any known issues with taking SEF while driving?

A: Official documents list Dizziness and Fatigue as common adverse reactions. Those experiencing these neurological effects are advised to use caution when performing tasks that require mental alertness, such as driving or operating machinery.


Q: Can SEF cause changes in mood?

A: Changes in mood, such as anxiety or nervousness, have been reported as adverse reactions. Since adverse reactions are categorized as neurological in nature, patients are advised to monitor for these kinds of effects during treatment.


Q: How is SEF generally eliminated from the body?

A: The drug is primarily eliminated from the body unchanged via renal excretion, meaning it is cleared through the kidneys. This information is part of the clinical pharmacology data and explains why dose adjustments are required for patients with impaired renal function.

How should SEF be stored and disposed of?

Official Storage and Disposal Requirements for SEF

This information is based strictly on the regulatory labeling for SEF, ensuring product quality and safety.


Storage Conditions

Requirement Regulatory Statement
Temperature Store at controlled room temperature (e.g., 20°C to 25°C). Do not freeze or expose to excessive heat.
Protection Keep in the original container to protect from light and moisture.
Child Safety Keep SEF out of the sight and reach of children at all times.
Stability Do not use past the labeled expiration date or beyond the specified in-use period after opening/reconstitution.

Disposal Instructions

Dispose of unused or expired SEF through an authorized drug take-back program or a licensed pharmaceutical waste collector. The medicine should not be disposed of by flushing it down a toilet or pouring it down a sink. If a take-back program is unavailable, follow specific label instructions for disposal in household trash, which typically involves mixing it with an unappealing substance like coffee grounds.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of SEF found in:

A-Z Index: